CN102250202B - 1-对硝基苯基-β-咔啉-3-甲酰氨基酸苄酯及其合成方法和应用 - Google Patents
1-对硝基苯基-β-咔啉-3-甲酰氨基酸苄酯及其合成方法和应用 Download PDFInfo
- Publication number
- CN102250202B CN102250202B CN 201010177112 CN201010177112A CN102250202B CN 102250202 B CN102250202 B CN 102250202B CN 201010177112 CN201010177112 CN 201010177112 CN 201010177112 A CN201010177112 A CN 201010177112A CN 102250202 B CN102250202 B CN 102250202B
- Authority
- CN
- China
- Prior art keywords
- residue
- lin
- nitrophenyl
- benzyl ester
- tetrahydrochysene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002253 acid Substances 0.000 title abstract 3
- 150000004657 carbamic acid derivatives Chemical class 0.000 title abstract 3
- 238000001308 synthesis method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 7
- -1 benzyl ester compound Chemical class 0.000 claims description 84
- 229940024606 amino acid Drugs 0.000 claims description 59
- 235000001014 amino acid Nutrition 0.000 claims description 58
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 50
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 42
- 238000002360 preparation method Methods 0.000 claims description 40
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 36
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 33
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 26
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 18
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 14
- KCUNTYMNJVXYKZ-JTQLQIEISA-N methyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound C1=CC=C2C(C[C@H](N)C(=O)OC)=CNC2=C1 KCUNTYMNJVXYKZ-JTQLQIEISA-N 0.000 claims description 14
- 229960002429 proline Drugs 0.000 claims description 13
- 230000008878 coupling Effects 0.000 claims description 12
- 238000010168 coupling process Methods 0.000 claims description 12
- 238000005859 coupling reaction Methods 0.000 claims description 12
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 11
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 11
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 10
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 9
- 229930182817 methionine Natural products 0.000 claims description 9
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 9
- BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 8
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 238000004440 column chromatography Methods 0.000 claims description 6
- 239000012043 crude product Substances 0.000 claims description 5
- 229960002989 glutamic acid Drugs 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 4
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims description 4
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 claims description 4
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims description 4
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims description 4
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- 239000012286 potassium permanganate Substances 0.000 claims description 4
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 229960004799 tryptophan Drugs 0.000 claims description 4
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
- JXYACYYPACQCDM-UHFFFAOYSA-N Benzyl glycinate Chemical compound NCC(=O)OCC1=CC=CC=C1 JXYACYYPACQCDM-UHFFFAOYSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- 238000006929 Pictet-Spengler synthesis reaction Methods 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- 239000006035 Tryptophane Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 229960005261 aspartic acid Drugs 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- BVCTWRNVKLXEQC-HNNXBMFYSA-N benzyl (2s)-2-amino-3-(4-hydroxyphenyl)propanoate Chemical compound C([C@H](N)C(=O)OCC=1C=CC=CC=1)C1=CC=C(O)C=C1 BVCTWRNVKLXEQC-HNNXBMFYSA-N 0.000 claims description 3
- IIDNACBMUWTYIV-VIFPVBQESA-N benzyl (2s)-2-amino-3-hydroxypropanoate Chemical compound OC[C@H](N)C(=O)OCC1=CC=CC=C1 IIDNACBMUWTYIV-VIFPVBQESA-N 0.000 claims description 3
- FPRSPUHXEPWUBZ-HNNXBMFYSA-N benzyl (2s)-2-amino-3-phenylpropanoate Chemical compound C([C@H](N)C(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 FPRSPUHXEPWUBZ-HNNXBMFYSA-N 0.000 claims description 3
- MBRRYUQWSOODEO-LBPRGKRZSA-N benzyl (2s)-2-amino-4-methylpentanoate Chemical compound CC(C)C[C@H](N)C(=O)OCC1=CC=CC=C1 MBRRYUQWSOODEO-LBPRGKRZSA-N 0.000 claims description 3
- TZPOCDBWQWIDSX-JQWIXIFHSA-N benzyl (2s,3s)-2-amino-3-methylpentanoate Chemical compound CC[C@H](C)[C@H](N)C(=O)OCC1=CC=CC=C1 TZPOCDBWQWIDSX-JQWIXIFHSA-N 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 238000009833 condensation Methods 0.000 claims description 3
- 230000005494 condensation Effects 0.000 claims description 3
- 229910000071 diazene Inorganic materials 0.000 claims description 3
- 229960004452 methionine Drugs 0.000 claims description 3
- 150000004702 methyl esters Chemical class 0.000 claims description 3
- 238000007127 saponification reaction Methods 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 9
- 210000004881 tumor cell Anatomy 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 241000699670 Mus sp. Species 0.000 abstract description 2
- 230000004614 tumor growth Effects 0.000 abstract description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 38
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 37
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 34
- 239000000243 solution Substances 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000000259 anti-tumor effect Effects 0.000 description 10
- 230000006837 decompression Effects 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 244000061458 Solanum melongena Species 0.000 description 5
- 235000002597 Solanum melongena Nutrition 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 3
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- JGMXNNSYEFOBHQ-OWOJBTEDSA-N 2-[(e)-4-morpholin-4-ylbut-2-enyl]-1,1-dioxothieno[3,2-e]thiazine-6-sulfonamide Chemical compound O=S1(=O)C=2SC(S(=O)(=O)N)=CC=2C=CN1C\C=C\CN1CCOCC1 JGMXNNSYEFOBHQ-OWOJBTEDSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 2
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 2
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 2
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 1
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- BCKJGHFFUBJJJY-AWEZNQCLSA-N benzyl (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-methylsulfanylbutanoate Chemical compound CC(C)(C)OC(=O)N[C@@H](CCSC)C(=O)OCC1=CC=CC=C1 BCKJGHFFUBJJJY-AWEZNQCLSA-N 0.000 description 1
- AXIQMEOYYYWDKF-LBPRGKRZSA-N benzyl (2s)-2-amino-3-(1h-imidazol-5-yl)propanoate Chemical compound C([C@H](N)C(=O)OCC=1C=CC=CC=1)C1=CNC=N1 AXIQMEOYYYWDKF-LBPRGKRZSA-N 0.000 description 1
- TYQYRKDGHAPZRF-INIZCTEOSA-N benzyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound O=C([C@H](CC=1C2=CC=CC=C2NC=1)N)OCC1=CC=CC=C1 TYQYRKDGHAPZRF-INIZCTEOSA-N 0.000 description 1
- YGYLYUIRSJSFJS-QMMMGPOBSA-N benzyl (2s)-2-aminopropanoate Chemical compound C[C@H](N)C(=O)OCC1=CC=CC=C1 YGYLYUIRSJSFJS-QMMMGPOBSA-N 0.000 description 1
- QQBUEAQIKXPFPP-NSHDSACASA-N benzyl (2s)-5-(diaminomethylideneamino)-2-nitramidopentanoate Chemical compound NC(=N)NCCC[C@H](N[N+]([O-])=O)C(=O)OCC1=CC=CC=C1 QQBUEAQIKXPFPP-NSHDSACASA-N 0.000 description 1
- IHRYAQVOEVWURS-SCZZXKLOSA-N benzyl (2s,3r)-2-amino-3-hydroxybutanoate Chemical compound C[C@@H](O)[C@H](N)C(=O)OCC1=CC=CC=C1 IHRYAQVOEVWURS-SCZZXKLOSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 102000054896 human PML Human genes 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- XNFNGGQRDXFYMM-PPHPATTJSA-N methyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate;hydrochloride Chemical compound Cl.C1=CC=C2C(C[C@H](N)C(=O)OC)=CNC2=C1 XNFNGGQRDXFYMM-PPHPATTJSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Description
技术领域
本发明涉及一类1-对硝基苯基-β-咔啉-3-甲酰氨基酸苄酯化合物,还涉及它们的合成方法,涉及它们对肿瘤细胞增殖的抑制作用,进一步涉及它们对荷瘤S180小鼠肿瘤生长的抑制作用和作为抗肿瘤剂的临床应用前景。本发明属于生物医药领域。
背景技术
恶性肿瘤是多发性疾病,对人类健康造成了严重危害。西方国家的恶性肿瘤的死亡率略低于血管疾病,居疾病死因第二位。我国城市地区的恶性肿瘤的死亡率大约是1.3/1000,其中男性恶性肿瘤病人的死亡率大约为1.6/1000、女性恶性肿瘤病人的死亡率大约为1/1000,居疾病死因第一位。我国农村地区的恶性肿瘤的死亡率大约为1.05/10000,其中男性恶性肿瘤病人的死亡率大约为1.3/1000、女性恶性肿瘤病人的死亡率大约为0.8/1000,居疾病死因第二位。
肿瘤的治疗方法有手术治疗,放射治疗和药物治疗(化学治疗)。目前,化学治疗仍然是临床治疗多种类型恶性肿瘤的主要手段。因此,寻找新的化学治疗药物是人类与恶性肿瘤抗争中的重要任务。
β-咔啉类生物碱是一类广泛研究的化合物,具有广泛的药理活性。在癌症发病率不断升高的当今,β-咔啉类生物碱的抗肿瘤活性引起了人们的关注。β-咔啉对多种人肿瘤细胞具有细胞毒。β-咔啉不仅能够抑制细胞周期蛋白依赖性激酶、IγB激酶复合物(IγK)和DNA的合成,而且能嵌入DNA双螺旋中抑制拓扑异构酶I和II,引起DNA损伤。β-咔啉的DNA嵌入能力还可以稳定DNA双螺旋结构,抑制DNA复制。这些作用使得β-咔啉成为抗肿瘤药物的重要先导结构。
发明人认识到在β-咔啉-3-羧酸母核的1位引入芳香基团,在3位引入氨基酸苄酯能够增强β-咔啉-3-羧酸母核的抗肿瘤活性。按照这种设计思路,发明人提出了本发明。
发明内容
本发明的第一个目的是提供具有抗肿瘤活性的平面结构的1-对硝基苯基咔啉衍生物;
本发明的第二个目的是提供一种合成上述1-对硝基苯基咔啉衍生物的方法;
本发明的第三个目的是将上述1-对硝基苯基咔啉衍生物应用于抗肿瘤剂。
本发明的上述目的是通过以下技术方案来实现的:
具有抗肿瘤活性的1-对硝基苯基-β-咔啉-3-甲酰氨基酸苄酯,其结构式为通式I所示:
通式中AA选自缬氨酸残基,丙氨酸残基,亮氨酸残基,异亮氨酸残基,苯丙氨酸残基,丝氨酸残基,色氨酸残基,酪氨酸残基,蛋氨酸残基,苄基保护的谷氨酸残基,苄基保护的天冬氨酸残基,脯氨酸残基,苏氨酸残基,甘氨酸残基,赖氨酸残基,精氨酸残基,谷氨酰胺残基或组氨酸残基。
在本发明优选的实施方式中,所述AA选自L-缬氨酸残基,L-丙氨酸残基,L-亮氨酸残基,L-异亮氨酸残基,L-苯丙氨酸残基,L-丝氨酸残基,L-色氨酸残基,L-酪氨酸残基,L-蛋氨酸残基,苄基保护的L-谷氨酸残基,苄基保护的L-天冬氨酸残基,L-脯氨酸残基,L-苏氨酸残基,甘氨酸残基,L-赖氨酸残基,L-精氨酸残基,L-谷氨酰胺残基或L-组氨酸残基。
本发明还提供一种上述通式I化合物的中间体,其结构式为通式II所示:
通式中AA选自缬氨酸残基,丙氨酸残基,亮氨酸残基,异亮氨酸残基,苯丙氨酸残基,丝氨酸残基,色氨酸残基,酪氨酸残基,蛋氨酸残基,苄基保护的谷氨酸残基,苄基保护的天冬氨酸残基,脯氨酸残基,苏氨酸残基,甘氨酸残基,赖氨酸残基,硝基保护的精氨酸残基,谷氨酰胺残基或组氨酸残基。
在本发明优选的实施方式中,所述AA选自L-缬氨酸残基,L-丙氨酸残基,L-亮氨酸残基,L-异亮氨酸残基,L-苯丙氨酸残基,L-丝氨酸残基,L-色氨酸残基,L-酪氨酸残基,L-蛋氨酸残基,苄基保护的L-谷氨酸残基,苄基保护的L-天冬氨酸残基,L-脯氨酸残基,L-苏氨酸残基,甘氨酸残基,L-赖氨酸残基,硝基保护的L-精氨酸残基,L-谷氨酰胺残基或L-组氨酸残基。
本发明还提供一种合成上述通式I或II所示化合物的方法,包括如下步骤:
1)制备色氨酸甲酯;
2)由色氨酸甲酯与对硝基苯甲醛制备(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯;
3)将(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯皂化,制备得(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸;
4)将(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸与氨基酸苄酯或其衍生物偶联制备得到通式II所示的(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉酰氨基酸苄酯;
5)将(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉酰氨基酸苄酯氧化制备得到平面结构的通式I所示的1-对硝基苯基-β-咔啉-3-甲酰氨基酸苄酯。
其中步骤1)中所述的色氨酸甲酯的制备可参考以下制备方法得到:在甲醇溶液中滴加二氯亚砜,然后加入色氨酸,制备得到色氨酸甲酯;
步骤2)中所述的(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯的制备可参考以下制备方法得到:在浓盐酸的甲醇溶液中,色氨酸甲酯与对硝基苯甲醛进行Pictet-SpengLer缩合,得到的(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯粗品用柱色谱进行分离,得到(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯纯品;
步骤3)中所述的(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸的制备可参考以下制备方法:冰盐浴下向(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯四氢呋喃溶液滴加2N氢氧化钠溶液至pH为12,制备得到(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸;
步骤(4)中所述的偶联反应采用以下方法:在二环己基羰二亚胺(DCC),N-羟基苯并三氮唑(HOBt)和N-甲基吗啉(NMM)存在下,将(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸与氨基酸苄酯或其衍生物偶联制备(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉酰氨基酸苄酯;
其中所述氨基酸苄酯或其衍生物是指氨基酸苄酯或双苄酯、保护基保护的氨基酸苄酯或双苄酯,所述保护基包括叔丁氧羰基、硝基等常见氨基酸保护基团。
本发明优选的氨基酸苄酯或其衍生物选自缬氨酸苄酯,丙氨酸苄酯,亮氨酸苄酯,异亮氨酸苄酯,苯丙氨酸苄酯,丝氨酸苄酯,色氨酸苄酯,酪氨酸苄酯,蛋氨酸苄酯,谷氨酸双苄酯,天冬氨酸双苄酯,苏氨酸苄酯,甘氨酸苄酯,叔丁氧羰基赖氨酸苄酯,硝基精氨酸苄酯,谷氨酰胺苄酯或组氨酸苄酯;更优选L-构型的氨基酸。
其中当偶联脯氨酸苄酯时,先把(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸制备为N-叔丁氧羰基-(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸,再与脯氨酸苄酯偶联,然后在盐酸乙酸乙酯溶液中脱去叔丁氧羰基;
步骤(5)中所述的1-对硝基苯基-β-咔啉-3-甲酰氨基酸苄酯的制备可参考以下制备方法:向(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉酰氨基酸苄酯的丙酮溶液中加入高锰酸钾,制备得到1-对硝基苯基-β-咔啉-3-甲酰氨基酸苄酯。
本发明通过体外和体内抗肿瘤活性试验表明,本发明通式I化合物具有优秀的抗肿瘤活性,从而提供所述通式I化合物在制备抗肿瘤药物中的应用。
附图说明
图1为本发明化合物的合成路线图;i)甲醇和二氯亚砜;ii)对硝基苯甲醛和浓盐酸的甲醇溶液;iii)四氢呋喃和2N氢氧化钠溶液;iv)DCC,HOBt,四氢呋喃和NMM;v)丙酮和高锰酸钾。
具体实施方式
为了进一步阐述本发明,下面给出一系列实施例。这些实施例完全是例证性的,它们仅用来对本发明进行具体描述,不应当理解为对本发明的限制。
实施例1制备L-色氨酸甲酯
冰-盐浴下,向150ml甲醇中边搅拌边滴加15ml二氯亚砜,半小时后加入L-色氨酸10.2g(50mmol),撤去冰盐浴,室温搅拌两天。TLC板显示原料基本消失后停止反应。减压去除甲醇。残留物用甲醇溶解并减压去除甲醇。该操作重复三次。残留物用乙醚溶解并减压去除乙醚。该操作重复三次。最后用甲醇/乙醚重结晶,经过两次重结晶共得到白色固体12.6g(99.0%)。Mp:218-220℃;ESI+-MS(m/e):219[M+H]+.
实施例2制备(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯
在30ml甲醇中缓慢加入5ml浓盐酸,向该溶液中加入2.55g(10mmol)L-色氨酸甲酯盐酸盐和1.66g(11mmol)对硝基苯甲醛,微波加热75℃反应两小时,TLC板显示基本反应完全。用浓氨水调pH值至6,过滤得到黄色固体。用石油醚/乙酸乙酯进行柱层析,得到(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯0.64g(18.2%)。Mp:197-198℃;ESI-MS(m/e):352[M+H]+;1H-NMR(300MHz,DMSO-d6):δ/ppm=10.695(s,1H),8.206(d,J=8.7Hz,2H),7.573(d,J=8.4Hz,2H),7.477(d,J=7.8Hz,1H),7.261(d,J=7.8Hz,1H),7.086-6.965(m,2H),5.483(s,1H),3.817-3.779(m,1H),3.638(s,3H),3.100(dd,J=5.1Hz,J=15.3Hz,1H),2.943(dd,J=7.2Hz,J=14.7Hz,1H);13C-NMR(75MHz,DMSO-d6):δ/ppm=174.21,151.28,147.22,136.7,133.68,130.05,130.05,126.93,123.81,123.81,121.60,119.01,118.28,111.62,107.37,53.89,52.43,52.16,25.14.
实施例3制备(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸
冰盐浴搅拌下用四氢呋喃溶解3.51g(10mmol)(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯,滴加2N氢氧化钠溶液调节pH值至12,用TLC板检测反应。原料点基本消失后,用2N盐酸液调节pH值至5-6,过滤,滤渣用蒸馏水洗,干燥得到黄色固体3.1g(92%)。Mp:183-184℃;ESI-MS(m/e):338[M+H]+;1H-NMR(300MHz,DMSO-d6):δ/ppm=10.883(s,1H),8.243(d,J=7.8Hz,2H),7.636(d,J=7.8Hz,2H),7.535(d,J=7.2Hz,1H),7.290(d,J=7.8Hz,1H),7.103-7.029(m,2H),5.805(s,1H),4.046-3.992(m,1H),3.284(d,J=12.3Hz,1H),3.099-3.025(m,1H);13C-NMR(75MHz,DMSO-d6):δ/ppm=172.99,151.28,147.88,146.99,136.94,131.21,131.21,130.91,126.48,123.86,123.86,122.15,119.33,118.57,111.83,107.40,53.94,52.22,14.55.
实施例4制备(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-甲酰氨基酸苄酯(4a-4r)
在50ml茄瓶里加入337mg(1mmol)(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸,加入3ml无水四氢呋喃溶解,冰浴下搅拌,加入HOBt 162mg(1.2mmol),DCC247mg(1.2mmol)形成A液。在25ml茄瓶中加入1.05mmolL-氨基酸苄酯或其衍生物,四氢呋喃或DMF溶解,加入NMM调pH形成B液。半小时后向A液中加入B液,加入NMM调节pH至8-9。TLC板检测反应进度。反应完成后过滤除去二环己基脲(DCU),减压浓缩除去溶剂,加乙酸乙酯溶解,分别用5%碳酸氢钠溶液,饱和氯化钠溶液,5%硫酸氢钾溶液,饱和氯化钠溶液,饱和碳酸氢钠溶液,饱和氯化钠溶液各洗3遍。乙酸乙酯层用无水硫酸钠干燥1小时,过滤,减压浓缩除去溶剂,得到粗产物。再通过柱色谱进行分离得到纯品。洗脱剂。石油醚∶乙酸乙酯5∶1-3∶1梯度洗脱。
(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-甲酰-L-缬氨酸苄酯(4a)
产量:280mg(53%)。Mp:97-98℃;ESI-MS(m/e):527[M+H]+。1H-NMR(300MHz,DMSO-d6):δ/ppm=10.836(s,1H),8.208(d,J=8.7Hz,1H),8.099(d,J=8.1Hz,2H),7.520(d,J=8.4Hz,2H),7.439-7.282(m,7H),7.103-6.981(m,2H),5.370(s,1H),5.143(dd,J=12.6Hz,J=20.1Hz,2H),4.236(dd,J=6.0Hz,J=7.8Hz,2H),3.566-3.521(m,1H),3.442-3.391(m,1H),2.953(dd,J=4.5Hz,J=15.0Hz,2H),2.142-2.032(m,1H),0.882(dd,J=1.8Hz,J=6.6Hz,2H);13C-NMR(75MHz,DMSO-d6):δ/ppm=173.51,151.22,147.07,136.59,136.33,133.71,129.96,129.96,129.96,129.96,128.59,127.07,127.07,127.07,123.76,121,60,121.60,119.00,118.19,111.62,108.60,66.43,57.84,53.67,52.09,30.38,25.53,19.42,18.70.
(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-甲酰-L-丙氨酸苄酯(4b)
产量:302mg(61%)。Mp:88-89℃;ESI-MS(m/e):499[M+H]+;1H-NMR(300MHz,DMSO-d6):δ/ppm=10.845(s,1H),8.312(d,J=7.2Hz,1H),8.204(d,J=8.7Hz,2H),7.513(d,J=8.7Hz,2H),7.434-7.286(m,7H),7.104-6.984(m,2H),5.369(s,1H),5.126(dd,J=12.6Hz,J=15.6Hz,2H),4.323(dq,J=7.2Hz,J=28.8Hz,1H),3.525-3.452(m,1H),2.954-2.891(m,1H),2.735-2.643(m,1H),1.322(d,J=7.2Hz,3H);13C-NMR(75MHz,DMSO-d6):δ/ppm=173.08,172.81,151.24,147.05,136.58,136.44,133.64,129.99,129.99,128.87,128.87,128.49,128.25,128.25,127.07,123.73,123.73,121.60,119.01,118.16,111.63,108.59,66.40,53.60,51.91,48.06,33.82,24.93,17.32.
(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-甲酰-L-异亮氨酸苄酯(4c)
产量:270mg(50%)。Mp:64-65℃;ESI-MS(m/e):541[M+H]+;1H-NMR(300MHz,DMSO-d6):δ/ppm=10.836(s,1H),8.238(d,J=10.8Hz,2H),8.106(d,J=7.8Hz,1H),7.509(d,J=5.7Hz,2H),7.433-7.278(m,7H),7.100-6.978(m,2H),5.364(s,1H),5.136(dd,J=12.3Hz,J=21.6Hz,2H),4.309-4.221(m,1H),3.536(m,1H),3.421-3.380(m,1H),2.943(dd,J=4.8Hz,J=15.3Hz,1H),2.679(dd,J=9.0Hz,J=15.3Hz,1H),1.425-1.319(m,2H),0.855-0.786(m,2H);13C-NMR(75MHz,DMSO-d6):δ/ppm=173.40,171.62,151.20,147.10,136.63,136.33,133.71,129.94,129.94,128.86,128.57,128.57,128.54,128.46,127.09,123.74,123.74,121.59,118.99,118.18,111.62,108.62,66.40,56.93,53.71,52.10,36.74,33.81,25.32,15.92,11.62.
(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-甲酰-L-天冬氨酸双苄酯(4d)
产量:240mg(38%)。Mp:62-63℃;ESI-MS(m/e):633[M+H]+;1H-NMR(500MHz,DMSO-d6):δ/ppm=0.8379(s,1H),8.4945(d,J=8.1Hz,1H),8.1957(d,J=8.75Hz,2H),7.5091(d,J=8.75Hz,2H),7.428(d,J=7.75Hz,1H),7.3732-7.2901(m,11H),7.846(d,J=7.1Hz,1H),7.0316-7.002(m,1H),5.3674(d,J=4.95Hz,1H),5.1061-5.0519(m,4H),4.8092(dd,J=6.55Hz,J=14.3Hz,1H),3.4869-3.4581(m,1H),2.9789-2.8555(m,3H),2.7447-2.6971(m,1H);13C-NMR(125MHz,DMSO-d6):δ/ppm=173.0731,170.8998,151.0162,147.1440,136.6700,136.2904,136.1795,133.6659,129.9860,129.9860,128.8383,128.8383,128.8383,128.8383,128.7060,128.5014,128.5014,128.5014,128.4615,128.3500,128.2282,127.0990,123.7365,123.7365,121.6116,119.0032,118.1784,111.6411,108.5940,66.8314,66.3826,53.7366,52.2976,48.9695,36.2276,25.2634.
(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-甲酰-L-酪氨酸苄酯(4e)
产量:140mg(24%)。Mp:110-111℃;ESI-MS(m/e):591[M+H]+;1H-NMR(300MHz,DMSO-d6):δ/ppm=10.836(s,1H),9.274(s,1H),8.195(d,J=8.7Hz,3H),7.479(d,J=8.7Hz,2H),7.431(d,J=7.5Hz,1H),7.361-7.277(m,7H),7.100-6.968(m,5H),5.276(s,1H),5.078(s,2H),4.473((dd,J=4.5Hz,J=14.1Hz,1H),3.458-3.414(m,1H),2.944-2.869(m,3H),2.745-2.665(m,1H);13C-NMR(75MHz,DMSO-d6):δ/ppm=173.06,71.79,156.61,151.00,147.09,136.59,136.23,133.65,130.59,129.92,128.81,128.48,128.36,127.26,127.07,123.72,121.60,118.99,118.19,115.59,111.62,108.57,66.44,54.26,53.65,52.31,40.83,40.55,39.44,39.16,36.28,25.06.
(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-甲酰-L-甲硫氨酸苄酯(4f)
产量:183mg(33%)。Mp:67-68℃;ESI-MS(m/e):559[M+H]+;1H-NMR(300MHz,DMSO-d6):δ/ppm=10.834(s,1H),8.307(d,J=7.5Hz,1H),8.204(d,J=8.7Hz,2H),7.524(d,J=9.0Hz,2H),7.437-7.280(m,7H),7.101-6.981(m,2H),5.369(s,1H),5.136(dd,J=12.3Hz,J=16.2Hz,2H),4.502-4.431(m,1H),3.507-3.462(m,1H),2.948(dd,J=4.5Hz,J=15.3,1H),2.713(dd,J=9.0Hz,J=15.0Hz,1H),2.013-1.975(m,6H);13C-NMR(75MHz,DMSO-d6):δ/ppm=173.46,172.00,151.20,147.07,136.59,136.36,133.68,129.97,128.88,128.88,128.55,128.55,128.39,128.39,127.06,123.76,123.76,121.60,119.00,118.18,111.63,108.52,66.56,53.65,52.13,51.47,30.82,29.93,25.51,14.98.
(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-甲酰-L-丝氨酸苄酯(4g)
产量:160mg(31%)。Mp:80-81℃;ESI-MS(m/e):515[M+H]E+;1H-NMR(300MHz,DMSO-d6):δ/ppm=10.851(s,1H),8.272~8.188(m,2H),7.933(d,J=8.4Hz,1H),7.572-7.490(m,1H),7.466-7.427(m,1H),7.364-7.286(m,6H),7.107-6.984(m2H),5.410(s,1H),5.143(s,2H),4.497-4.417(m,1H),3.827-3.774(m,1H),3.692(dd,J=4.2Hz,J=11.1Hz,1H),2.991(dd,J=4.5Hz,J=12.3Hz,1H),2.759-2.678(m,1H);13C-NMR(75MHz,DMSO-d6):δ/ppm=173.11,170.81,150.78,147.78,147.12,143.30,136.39,133.51,130.41,130.11,130.11,128.84,128.43,128.14,128.14,127.08,124.61,124.61,121.65,119.02,118.22,111.63,108.75,66.46,61.61,55.05,53.75,52.01,40.81,40.54,40.26,39.98,39.70,39.43,39.15,25.27.
(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-甲酰-L-亮氨酸苄酯(4h)
产量:216(40%)。Mp:65-66℃;ESI-MS(m/e):541[M+H]+;1H-NMR(300MHz,DMSO-d6):δ/ppm=10.829(s,1H),8.253-8.191(m,2H),7.513(s,J=8.7,2H),7.429-7.278(m,7H),7.040(s,J=6.9,2H),5.120(s,2H),4.387-4.315(m,1H),3.538-3.491(m,1H),2.939(dd,J=4.8,J=15.3,1H),2.696(dd,J=9.0,J=15.0,1H),1.691-1.531(m,3H),0.885(d,J=5.7,3H),0.839(d,J=6.3,3H);13C-NMR(75MHz,DMSO-d6):δ/ppm=173.39,172.69,151.24,147.06,136.59.136.39,133.66,129.96,128.88,128.88,128.52,128.46,128.33,128.33,127.06,123.77,123.77,121.58,118.99,118.16,111.62,108.50,66.41,53.63,52.97,52.08,50.85,25.57,24.71,24.61,23.14.
(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-甲酰-L-苏氨酸苄酯(4i)
产量:170mg(32%)。Mp:82-83℃;ESI-MS(m/e):551[M+Na]+;1H-NMR(300MHz,DMSO-d6):δ/ppm=10.837(s,1H),8.200(d,J=8.1Hz,2H),8.028(d,J=8.1Hz,1H),7.532(d,J=7.5Hz,2H),7.451(d,J=7.5Hz,1H),7.357-7.283(m,7H),5.393(s,1H),5.134(s,2H),4.347(d,J=8.1Hz,1H),4.175(d,J=11.4Hz,1H),3.537(s,1H),3.047-2.993(m,1H),2.750(dd,J=7.5Hz,J=15.3Hz,1H);13C-NMR(75MHz,DMSO-d6):δ/ppm=173.47,170.95,150.90,147.10,136.62,136.40,133.75,130.02,128.83,128.83,128.41,128.41,128.14,128.14,127.12,123.78,128.78,121.62,118.99,118.26,111.61,108.90,66.76,66.43,58.15,53.90,52.36,25.10,20.86.
(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-甲酰-L-色氨酸苄酯(4j)
产量:190mg(31%)。Mp:86-87℃;ESI-MS(m/e):614[M+H]+;1H-NMR(300MHz,DMSO-d6):δ/ppm=10.934(s,1H),10.810(s,1H),8.253(d,J=7.5Hz,1H),8.158(d,J=8.1Hz,1H),7.957(s,1H),7.510(d,J=7.8Hz,1H),7.446-7.373(m,3H),7.312-7.281(m,4H),7.205-6.944(m,7H),5.269(s,1H),4.638-4.574(m,1H),3.209-3.168(m,1H),2.957-2.890(m,2H),2.734-2.650(m,2H);13C-NMR(75MHz,DMSO-d6):δ/ppm=173.10,172.04,162.77,150.97,147.03,136.58,136.21,133.64,129.90,129.90,128.79,128.79,128.44,128.44,128.23,128.23,127.61,127.07,124.31,123.70,123.70,121.61,121.50,118.96,118.57,118.20,111.94,111.63,109.52,108.67,66.47,53.67,53.52,52.14,36.24,31.23.
(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉酰甘氨酸苄酯(4k)
产量:122mg(25%)。Mp:79-80℃;ESI+-MS(m/e):485[M+H]+;1H-NMR(300MHz,DMSO-d6):δ/ppm=10.835(s,1H),8.389(d,J=6.0Hz,1H),8.211(d,J=8.7Hz,2H),7.542(d,J=8.7Hz,2H),7.462(d,J=7.5Hz,1H),7.373-7.282(m,6H),7.104-6.979(m,1H),5.396(d,J=4.5Hz,1H),3.940(d,J=6.0Hz,2H),3.497-3.451(m,1H)2.979(dd,J=4.5Hz,J=15.0Hz,1H),2.814-2.763(m,1H);13C-NMR(75MHz,DMSO-d6):δ/ppm=173.55,170.23,162.77,151.06,147.10,136.61,136.34,133.70,130.70,130.04,128.87,128.87,128.53,128.42,128.42,127.11,123.75,123.75,121.60,118.98,118.241,11.61,108.69,66.33,53.78,52.33,36.24,25.25.
(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-甲酰-L-苯丙氨酸苄酯(41)
产量:254mg(44%)。Mp:69-70℃;ESI-MS(m/e):575[M+H]+;1H-NMR(300MHz,DMSO-d6):δ/ppm=10.797(s,1H),8.309(d,J=7.5Hz,1H),8.194(d,J=8.7Hz,2H),7.486-7.185(m,1H),7.039(dt,J=7.2Hz,J=14.7Hz,1H),5.271(s,1H),5.088(s,2H),4.561(dd,J=7.8Hz,J=14.1Hz,1H),3.462-3.408(m,1H),3.120-2.950(m,2H),2.893(dd,J=4.5Hz,J=15.3Hz,1H),2.705(dd,J=9.0Hz,J=15.3Hz,1H);13C-NMR(75MHz,DMSO-d6):δ/ppm=173.11,171.69,151.03,147.08,137.42,136.58,136.19,133.61,129.93,129.63,129.63,129.52,128.83,128.77,128.69,128.69,128.51,128.37,128.37,128.25,127.05,123.73,123.73,121.59,118.99,118.17,111.62,108.49,53.98,53.60,52.31,36.94,32.30.
(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-甲酰-L-谷氨酸双苄酯(4m)
产量:236mg(38%)。Mp:68-69℃;ESI-MS(m/e):647[M+H]+;1H-NMR(300MHz,DMSO-d6):δ/ppm=10.812(s,1H),8.279(d,J=7.5Hz,1H),8.197-8.168(m,1H),8.179-8.168(m,2H),7.539-7.501(m,2H),7.433-7.300(m,11H),7.106-7.017(m,2H),5.373(d,J=3.6Hz,1H),5.124(s,2H),5.075(s,2H),2.953(dd,J=4.8Hz,J=15.3Hz,1H),2.705(dd,J=9.0Hz,J=15.0Hz,1H),2.518-2.431(m,2H),2.120-1.907(m,2H).
(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-甲酰-L-谷氨酰胺苄酯(4n)
产量:115mg(18%)。Mp:193-194℃;ESI+-MS(m/e):556[M+H]+;1H-NMR(300MHz,DMSO-d6):δ/ppm=10.850(s,1H),8.396(d,J=3.9Hz,1H),8.208(d,J=8.7Hz,2H),7.535(d,J=6.0Hz,2H),7.462-7.287(m,7H),7.046(dt,J=6.9Hz,J=14.7Hz,2H),5.380(s,1H),5.125(s,2H),4.307(dd,J=8.4Hz,J=12.6Hz,1H),3.495-3.454(m,1H),2.945(dd,J=4.5Hz,J=15.3Hz,1H),2.736-2.655(m,1H),2.159(d,J=7.5Hz,1H),2.064-1.952(m,1H),1.911-1.789(m,1H);13C-NMR(75MHz,DMSO-d6)δ/ppm=173.76,173.40,172.11,151.19,147.06,136.59,136.59,133.68,129.99,128.87,128.87,128.50,128.50,128.31,127.06,127.06,123.76,127.76,121.61,119.01,118.18,111.63,108.59,66.43,53.63,52.25,52.04,31.56,26.82,25.52.
(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-甲酰-L-组氨酸苄酯(4o)
产量:90mg(16%)。Mp:89-90℃;ESI+-MS(m/e):565[M+H]+;1H-NMR(300MHz,DMSO-d6):δ/ppm=10.838(s,1H),8.561-8.536(m,1H),8.202(d,J=8.7,1H),7.901(d,J=8.4,2H),7.601(d,J=8.4Hz,1H),7.549(d,J=8.7Hz,2H),7.102-6.976(m,1H),5.337(s,1H),5.070(s,2H),4.588(dd,J=6.3Hz,J=13.2Hz,1H),3.641(d,J=4.5Hz,1H),3.437(dd,J=5.1Hz,J=8.7Hz,1H),3.007-2.948(m,2H),2.799-2.718(m,1H),2.645(s,1H),2.411(s,1H);13C-NMR(75MHz,DMSO-d6):δ/ppm=172.96,171.57,150.85,147.10,143.32,136.60,136.34,135.54,133.64,130.02,128.80,128.80,128.42,128.19,128.19,128.17,127.10,126.68,124.41,124.41,123.75,110.39,110.39,66.38,65.49,54.52,53.63,31.16,28.94.
(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-甲酰-L-N-硝基精氨酸苄酯(4p)
产量:110mg(18%)。Mp:123-124℃;ESI+-MS(m/e):629[M+H]+;1H-NMR(300MHz,DMSO-d6):δ/ppm=10.831(s,1H),8.288(d,J=7.5Hz,1H),8.205(d,J=8.4Hz,2H),7.516(d,J=8.4Hz,2H),7.463-7.280(m,6H),7.040(dt,J=7.2Hz,J=14.7Hz,2H),4.366-4.297(m,1H),3.493(m,1H),3.150(dd,J=5.4Hz,2H),2.938(dd,J=4.5Hz,J=15.6Hz,1H),2.788-2.666(m,1H),1.808-1.621(m,1H),1.540(d,J=6.3Hz,2H);13C-NMR(75MHz,DMSO-d6):δ/ppm=173.42,172.16,159.78,151.18,147.18,147.07,136.07,136.59,136.33,133.66,129.98,129.98,128.88,128.88,128.53,128.34,128.34,127.05,123.77,123.77,121.60,119.00,118.18,111.62,108.52,66.51,53.65,52.23,52.10,40.82,40.54,40.26,39.98,39.70,37.43,39.15,30.07,28.44,25.52,25.52.
(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-甲酰-L-脯氨酸苄酯(4q)
冰浴下将337mg(1mmol)(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉羧酸悬浮于含280mg(1.3mmol)(Boc)2O的四氢呋喃溶液中,然后加三乙胺调节pH8-9,TLC板检测反应,原料点消失后减压除去四氢呋喃,用乙酸乙酯溶液残留物,然后用5%硫酸氢钾溶液洗涤3次,饱和氯化钠溶液洗涤3次,无水硫酸钠干燥,过滤,减压浓缩得到N-Boc-(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉羧酸。然后在50ml茄瓶里加入437mg(1mmol)N-Boc-(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸,加入3ml无水四氢呋喃溶解,冰浴下搅拌,加入HOBt 162mg(1.2mmol),DCC 247mg(1.2mmol)形成A液。在25ml茄瓶中加入1.05mmol氨基酸苄酯,四氢呋喃或DMF溶解,加入NMM调pH形成B液。半小时后向A液中加入B液,加入NMM调节pH至8-9。TLC板检测反应进度。反应完成后过滤除去DCU,减压浓缩除去溶剂,加乙酸乙酯溶解,分别用5%碳酸氢钠溶液,饱和氯化钠溶液,5%硫酸氢钾溶液,饱和氯化钠溶液,饱和碳酸氢钠溶液,饱和氯化钠溶液各洗3遍。乙酸乙酯层用无水硫酸钠干燥1小时,过滤,减压浓缩除去溶剂,得到粗产物。再通过柱色谱进行分离得到纯品。洗脱剂为石油醚:乙酸乙酯=5:1-3:1梯度洗脱。在冰盐浴搅拌下向N-Boc-(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉酰脯氨酸苄酯加入4N盐酸乙酸乙酯,反应结束后减压去除乙酸乙酯。残留物用乙酸乙酯溶解并减压去除乙酸乙酯。该操作重复三次。残留物用乙醚溶解并减压去除乙醚。该操作重复三次。得到180mg(34%)目标化合物,为泡状固体。Mp:164-165℃;ESI-MS(m/e):547[M+Na]+;1H-NMR(300MHz,DMSO-d6):δ/ppm=10.880(s,1H),8.245~8.187(m,3H),7.498(d,J=8.7Hz,2H),7.440(d,J=8.7Hz,1H),7.315~7.264(m,2H),7.106~6.931(m,3H),5.355(s,2H),5.116(dd,J=12.6Hz,J=18.6Hz,1H),4.378(dd,J=3.9Hz,J=8.7Hz,1H),4.03(dd,J=7.2Hz,J=14.4Hz,1H),3.631~3.603(m,1H),3.360(s,1H),2.889(s,1H),2.752-2.667(m,1H),2.193-2.083(m,1H),1.992(s,1H),1.885-1.712(m,1H);13C-NMR(75MHz,DMSO-d6):δ/ppm=172.17,171.37,151.10,146.95,136.53,136.46,133.43,130.07,128.89,128.89,128.50,128.25,128.25,127.97,127.11,123.69,123.69,121.62,118.96,118.26,111.60,108.56,66.27,59.01,53.61,49.97,46.61,29.00,24.89,14.55.
(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉酰赖氨酸苄酯(4r)
由L-NεBoc-赖氨酸苄酯得到(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉酰赖氨酸(Boc)苄酯。在冰盐浴搅拌下向(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉酰赖氨酸(Boc)苄酯加入4N盐酸乙酸乙酯,反应结束后减压去除乙酸乙酯。残留物用乙酸乙酯溶解并减压去除乙酸乙酯。该操作重复三次。残留物用乙醚溶解并减压去除乙醚。该操作重复三次。得到154mg(24%)目标化合物,为泡状固体。Mp:162-163℃;ESI-MS(m/e):556[M+H]+;1H-NMR(300MHz,DMSO-d6):δ/ppm=11.186(s,1H),8.275(d,J=8.4Hz,2H),8.103(s,1H),7.631(d,J=8.7Hz,1H),7.478-7.322(m,7H),7.191-7.069(m,2H),6.162(s,1H),5.159(s,1H),4.328-4.239(m,1H),3.734(m,1H),3.181(d,J=7.5Hz,1H),2.967(dd,J=10.5Hz,J=15.6Hz,1H),2.713(d,J=5.7Hz,2H),1.734(m,2H),1.559(m,2H),1.436-1.343(m,2H);13C-NMR(75MHz,DMSO-d6):δ/ppm=171.58,168.85,148.64,137.19,136.24,132.24,132.68,128.96,128.96,128.96,128.68,128.54,128.54,128.54,127.58,125.75,123.93,123.93,122.85,119.79,118.63,112.17,106.78,66.75,53.86,52.74,50.80,40.82,40.54,40.27,39.99,39.71,39.43,39.15,38.49,30.27,26.73,23.70,22.48,22.21.
实施例5制备1-对硝基苯基-β-咔啉-3-甲酰氨基酸苄酯
在50ml茄瓶中称取(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉酰氨基酸苄酯(4a-4r)0.3mmol,加3ml丙酮溶解,加入0.45mmol高锰酸钾室温下搅拌看,TLC板检测反应进程,原料消失后减压除去溶剂,然后加乙酸乙酯溶解,过滤除去二氧化锰,减压除去溶剂后加入5ml 1N盐酸溶液,搅拌3小时过滤,滤渣用蒸馏水洗,干燥后得到平面的苯基-咔啉酰氨基酸苄酯(5a-5r)。
1-对硝基苯基-β-咔啉-3-甲酰-L-缬氨酸苄酯(5a)
产量:78mg(50%)。Mp:181-183℃;ESI-MS(m/e):523[M+H]+; IR(KBr):3379,3234,2965,2934,1740,1657,1626,1522,1495,1458,1344,1246,1188,1150,854,741,698,613;1H-NMR(300MHz,DMSO-d6):δ/ppm=12.140(s,1H),8.965(s,1H),8.707(d,J=8.7Hz,1H),8.492(d,J=7.2Hz,2H),8.377(d,J=8.1Hz,2H),7.726-7.621(m,2H),7.398-7.336(m,7H),5.216(dd,J=12.6Hz,J=18Hz,2H),4.620-4.573(m,1H),2.333-2.247(m,1H),0.971(d,J=4.5Hz,6H);13C-NMR(75MHz,DMSO-d6):δ/ppm=171.70,164.93,148.02,144.04,142.26,139.57,138.70,136.26,135.26,131.15,130.34,130.34,129.61,129.38,128.90,128.90,128.61,128.57,124.47,124.47,122.79,121.54,121.07,114.88,113.16,66.71,57.90,31.00,19.54,18.60.
1-对硝基苯基-β-咔啉-3-甲酰-L-丙氨酸苄酯(5b)
产量:79mg(53%)。Mp:154-155℃;ESI-MS(m/e):495[M+H]+; IR(KBr):3379,3240,2361,2340,1744,1655,1520,1495,1450,1342,1306,1250,1198,1157,740,700,660;1H-NMR(300MHz,DMSO-d6):δ/ppm=10.845(s,1H),8.312(d,J=7.2Hz,1H),8.204(d,J=8.7Hz,2H),7.513(d,J=8.7Hz,2H),7.434-7.286(m,7H),7.104-6.984(m,2H),5.369(s,1H),5.126(dd,J=12.6Hz,J=15.6Hz,2H),4.323(dq,J=7.2Hz,J=28.8Hz,1H),3.525-3.452(m,1H),2.954-2.891(m,1H),2.735-2.643(m,1H),1.322(d,J=7.2Hz,3H);13C-NMR(75MHz,DMSO-d6):δ/ppm=173.08,172.81,151.24,147.05,136.58,136.44,133.64,129.99,129.99,128.87,128.87,128.49,128.25,128.25,127.07,123.73,123.73,121.60,119.01,118.16,111.63,108.59,66.40,53.60,51.91,48.06,33.82,24.93,17.32.
1-对硝基苯基-β-咔啉-3-甲酰-L-异亮氨酸苄酯(5c)
产量:87mg(54%)。Mp:217-218℃;ESI-MS(m/e):537[M+H]+; IR(KBr):3385,3208,2965,2934,2878,1742,1657,1520,1495,1452,1342,1248,1148,852,741,681;1H-NMR(300MHz,DMSO-d6):δ/ppm=12.097(s,1H),8.951(s,1H),8.826-8.376(m,6H),7.694-7.356(m,8H),5.216(s,2H),4.675(s,1H),2.087(m,1H),1.491(m,1H),1.246(m,1H),0.932(s,6H);13C-NMR(125MHz,DMSO-d6):δ/ppm=171.6737,164.8328,148.0128,144.0849,142.4084,139.4901,138.6732,136.2451,135.4129,131,1772,130.3156,130.3156,129.5664,128.8932,128.8932,128.5730,128.5730,124.4420,124.4420,122.7475,121.5724,121.0082,114.8498,113.2133,66.7137,56.9340,39.5507,25.3765,16.0361,11.6274.
1-对硝基苯基-β-咔啉-3-甲酰-L-天冬氨酸双苄酯(5d)
产量:87mg(47%)。Mp:191-192℃;ESI-MS(m/e):629[M+H]+; IR(KBr):3377,3250,3090,2926,1742,1651,1624,1600,1520,1495,1462,1345,1306,1175,851,741,696;1H-NMR(500MHz,DMSO-d6):δ/ppm=12.101(s,1H),9.246(d,J=8.7Hz,1H),8.961(s,1H),8.499-8.358(m,5H),7.734-7.623(m,2H),7.392-7.245(m,11H),5.173(s,4H),5.105(s,1H),3.300(s,2H);13C-NMR(75MHz,DMSO-d6):δ/ppm=171.03,170.91,164.97,148.00,143.96,142.21,139.61,138.52,135.05,131.11,130.42,130.42,130.42,129.66,129.59,129.41,129.27,128.99,128.81,128.75,128.57,128.40,128.24,128.11.124.31,124.31,124.31,122.71,121.50,121.07,114.99,113.09,52.84,52.19,49.16,36.47.
1-对硝基苯基-β-咔啉-3-甲酰-L-酪氨酸苄酯(5e)
产量:55mg(31%)。Mp:111-113℃;ESI-MS(m/e):587[M+H]+; IR(KBr):3321,2930,1728,1655,1626,1601,1516,1494,1447,1346,1242,1175,852,739,696,646,535;1H-NMR(300MHz,DMSO-d6):δ/ppm=12.098(s,1H),9.307(s,1H),8.935(s,1H),8.650(d,J=7.8Hz,1H),8.485(dd,J=8.7Hz,J=12.3Hz,3H),8.341(d,J=8.7Hz,2H),7.725-7.616(m,2H),7.351-7.250(m,2H);13C-NMR(75MHz,DMSO-d6):δ/ppm=171.74,164.70,756.74,148.01,143.91,142.21,139.57,138.42,136.25,135.16,131.19,130.79,130.79,130.34,130.34,129.61,128.86,128.86,128.55,128.48,128.48,126.92,124.33,124.33,122.78,121.52,121.08,115.74,115.65,114.76,113.14,66.65,53.85.
1-对硝基苯基-β-咔啉-3-甲酰-L-甲硫氨酸苄酯(5f)
产量:55mg(33%)。Mp:178-179℃;ESI-MS(m/e):555[M+H]+; IR(KBr):3375,3244,1738,1657,1624,1601,1518,1450,1342,1304,1246,1188,852,741,698,615;1H-NMR(300MHz,DMSO-d6):δ/ppm=12.082(s,1H),9.026-8.946(m,2H),7.676(d,J=16.8Hz,2H),7.335(m,7H),5.207(s,2H),4.860(s,1H),2.248(s,2H),2.051-1.641(m,5H);13C-NMR(75MHz,DMSO-d6):δ/ppm=172.06,165.40,147.95,144.05,142.22,139.89,138.58,136.42,135.19,131.11,130.54,130.54,129.55,128.86,128.86,128.49,128.27,124.27,124.27,122.73,121.55,121.03,114.95,113.15,66.63,51.97,30.94,30.36,15.11.
1-对硝基苯基-β-咔啉-3-甲酰-L-丝氨酸苄酯(5g)
产量:41mg(27%)。Mp:126-128℃;ESI-MS(m/e):511[M+H]+; IR(KBr):3374,1738,1659,1522,1495,1346,1244,853,741,696;1H-NMR(500MHz,DMSO-d6):δ/ppm=12.108(s,1H),8.980(s,1H),8.896(d,J=8.0Hz,1H),8.505-8.445(m,3H),8.387-8.342(m,2H),7.738-7.713(m,1H),7.669-7.639(m,1H),7.418-7.305(m,6H),5.226(s,2H),4.797(q,J=4.0Hz,2H),4.046-4.002(m,1H),3.892(dd,J=2.1Hz,J=6.6Hz,1H);13C-NMR(125MHz,DMSO-d6):δ/ppm=170.93,164.88,148.03,144.06,142.25,139.76,138.76,136.45,135.24,131.11,130.41,130.41,129.60,128.86,128.86,128.43,128.08,128.08,124.42,124.42,122.79,121.56,121.07,114.87,113.16,66.60,61.92,55.34.
1-对硝基苯基-β-咔啉-3-甲酰-L-亮氨酸苄酯(5h)
产量:69mg(43%)。Mp:113-114℃;ESI-MS(m/e):537[M+H]+; IR(KBr):3375,3198,3084,2953,2870,1740,1655,1516,1495,1464,1342,1248,1150,854,743,681;1H-NMR(300MHz,DMSO-d6):δ/ppm=12.065(s,1H),8.947(s,1H),8.854(d,J=8.4Hz,1H),8.497-8.349(m,5H),7.729-7.621(m,2H),7.406-7.274(m,6H),5.195(s,2H),4.803-4.727(m,1H),1.992-1.907(m,2H),1.803-1.657(m,2H),0.942(d,J=6.0Hz,6H);13C-NMR(75MHz,DMSO-d6):δ/ppm=172.67,165.10,148.00,144.03,142.08,139.93,136.43,131.10,130.49,130.39,130.08,129.58,128.90,128.86,128.52,128.28,128.23,126.16,124.36,124.31,122.68,121.52,121.06,114.93,113.10,66.54,47.90,33.76,25.79,25.05,23.55.
1-对硝基苯基-β-咔啉-3-甲酰-L-苏氨酸苄酯(5i)
产量:41mg(26%)。Mp:117-118℃;ESI-MS(m/e):525[M+H]+; IR(KBr):3387,1736,1659,1626,1603,1522,1495,1450,12346,1321,1244,852,741,698,675;1H-NMR(300MHz,DMSO-d6):δ/ppm=12.123(s,1H),8.989(s,1H),8.762(d,J=9.0Hz,8H),8.510-8.481(m,3H),8.347(d,J=9.0Hz,2H),7.724(d,J=8.0Hz,1H),7.654(t,J=7.5Hz,1H),7.420-7.306(m,6H),5.219(s,2H),4.698(dd,J=2.5Hz,J=9.0Hz,1H),4.383(dd,J=2.5Hz,J=7.5Hz,1H),2.093(s,1H),1.192(d,J=6.0Hz,3H);13C-NMR(75MHz,DMSO-d6):δ/ppm=171.065,165.206,148.045,144.073,142.263,139.636,138.795,136.438,135.286,131.126,130.334,130.334,129.609,128.863,128.829,128.438,128.142,128.142,124.486,124.486,122.800,121.560,121.071,114.903,113.168,67.088,66.610,58.439,21.056.
1-对硝基苯基-β-咔啉-3-甲酰-L-色氨酸苄酯(5j)
产量:102mg(56%)。Mp:112-113℃;ESI-MS(m/e):610[M+H]+; IR(KBr):3385,3061,2934,1732,1659,1520,1495,1460,1346,1178,852,741,698;1H-NMR(300MHz,DMSO-d6):δ/ppm=8.914(s,1H),8.47(d,J=8.7Hz,3H),8.209(d,J=8.7Hz,2H),7.718-7.527(m,3H),7.397-6.875(m,12H),5.168(s,2H),4.976(t,J=6.0Hz,1H),3.397(s,2H);13C-NMR(75MHz,DMSO-d6):δ/ppm=172.02,164.71,147.93,143.86,142.04,139.56,138.38,136.57,136.26,135.12,131.11,130.19,130.19,129.61,129.36,128.86,128.86,128.66,128.51,128.31,128.31,127.71,124.37,122.73,121.58,121.09,119.06,118.64,114.72,113.10,111.92,109.23,66.68,53.33,27.42.
1-对硝基苯基--β-咔啉-3-甲酰-甘氨酸苄酯(5k)
产量:54mg(38%)。Mp:190-191℃;ESI-MS(m/e):481[M+H]+;=0.5,丙酮);IR(KBr):3399,3227,1749,1657,1624,1601,1520,1495,1450,1345,1306,1248,1194,851,741;1H-NMR(300MHz,DMSO-d6):δ/ppm=12.073(s,1H),9.169(t,J=6.0Hz,1H),8.945(s,1H),8.778(d,J=4.5Hz,1H),8.517-8.435(m,6H),7.776-7.622(m,2H),7.399-7.365(m,4H),5.201(s,2H),4.240(d,J=6.0Hz,2H);13C-NMR(75MHz,DMSO-d6):δ/ppm=170.39,165.58,147.99,144.07,142.23,140.02,138.54,136.47,135.16,131.75,131.18,130.53,130.24,130.11,129.54,128.88,128.51,128.37,124.37,124.21,122.70,121.58,121.03,114.80,113.14,66.34,41.82.
1-对硝基苯基-β-咔啉-3-甲酰-L-苯丙氨酸苄酯(5I)
产量:91mg(53%)。Mp:201-202℃;ESI-MS(m/e):571[M+H]+; IR(KBr):3373,3221,2955,1746,1657,1624,1601,1562,1520,1495,1452,1342,1306,1171,851,739,698,494;1H-NMR(300MHz,DMSO-d6):δ/ppm=8.901(s,1H),8.809(d,J=5.1Hz,1H),8.507-8.444(m,3H),8.36(d,J=9.0Hz,2H),7.721-7.614(m,2H),7.373-7.222(m,11H),5.186(s,2H),4.978-4.908(m,1H),3.294(d,J=6.9Hz,2H);13C-NMR(75MHz,DMSO-d6):δ/ppm=171.66,164.88,14797,143.9,142.18,139.54,138.41,137.32,136.21,134.98,131.09,130.36,130.36,129.77,129.61,128.86,128.55,128.55,128.55,128.43,128.43,127.23,127.23,124.32,124.32,122.73,121.45,121.08,114.81,113.1,66.7,53.86,37.02.
1-对硝基苯基-β-咔啉-3-甲酰-L-谷氨酸双苄酯(5m)
产量:100mg(52%)。Mp:115-117℃;ESI-MS(m/e):643[M+H]+;=0.55,丙酮);IR(KBr):3364,3225,1742,1659,1599,1520,1495,1456,1310,1245,1175,1105,853,737,696;1H-NMR(300MHz,DMSO-d6):δ/ppm=12.089(s,1H),9.01(d,J=8.1Hz,1H),8.942(s,1H),8.465(m,5H),7.733-7.617(m,2H),7.38-7.278(m,11H),5.200(s,2H),5.037(s,2H),4.8234.749(m,1H),2.603-2.544(m,2H),2.387-2.190(m,2H);13C-NMR(75MHz,DMSO-d6):δ/ppm=172.84,172.02,165.39,147.93,144.02,142.21,139.81,138.58,136.49,136.40,135.19,131.11,130.54,130.54,129.55,128.84,128.84,128.77,128.77,128.47,128.36,128.26,128.26,128.22,128.22,124.24,124.24,122.71,121.56,121.04,115.00,113.15,66.63,66.01,52.24,30.64,26.58.
1-对硝基苯基-β-咔啉-3-甲酰-L-谷氨酰胺苄酯(5n)
产量:63mg(38%)。Mp:159-160℃;ESI-MS(m/e):552[M+H]+; IR(KBr):3408,3202,2932,2857,1720,1667,1518,1385,1346,12421,1107,852,737,696;1H-NMR(300MHz,DMSO-d6):δ/ppm=12.097(s,1H),9.167(d,J=7.5Hz,1H),8.547-8.432(m,4H),7.738-7.619(m,2H),7.407-7.255(m,7H),6.848(s,1H),5.196(s,1H),4.707-4.654(m,1H),2.261-2.119(m,4H);13C-NMR(75MHz,DMSO-d6):δ/ppm=172.19,165.38,147.94,144.01,142.21,139.93,138.50,136.47,135.14,131.16,130.61,130.61,129.54,128.86,128.86,128.46,128.46,128.21,128.21,124.30,124.30,122.71,121.56,121.03,114.87,113.15,66.48,52.97,31.68,26.65.
1-对硝基苯基-β-咔啉-3-甲酰-L-组氨酸苄酯(5o)
产量:60mg(36%)。Mp:196-197℃;ESI-MS(m/e):561[M+H]+; IR(KBr):3380,3149,2610,1742,1670,1622,1601,1520,1495,1346,1245,853,739;1H-NMR(300MHz,DMSO-d6):δ/ppm=14.400(s,1H),12.201(s,1H),9.146(d,J=8.1Hz,1H),9.106(s,1H),8.888(s,1H),8.472-8.440(m,5H),7.755-7.641(m,1H),7.463(s,1H),7.358-7.305(m,6H),5.219(s,2H),5.073(d,J=6.6Hz,1H),3.437(d,J=6.6Hz,2H);13C-NMR(75MHz,DMSO-d6):δ/ppm=170.95,165.57,147.96,143.93,142.25,139.57,138.53,136.23,135.18,134.26,131.10,130.59,130.59,129.92,129.58,128.85,128.85,128.54,128.27,128.27,124.30,124.30,122.70,121.48,121.06,117.47,115.00,113.23,66.89,63.69,26.61.
1-对硝基苯基-β-咔啉-3-甲酰-L-精氨酸苄酯(5p)
产量:93mg(49%)。Mp:153-154℃;ESI-MS(m/e):625[M+H]+; IR(KBr):3319,2930,2855,1736,1628,1601,1520,1495,1448,1346,1248,1188,1150,1105,852,740,679;1H-NMR(300MHz,DMSO-d6):δ/ppm=12.157(s,1H),8.941(s,2H),8.453(s,5H),8.085-7.927(m,2H),7.085-7.641(m,3H),7.379-7.312(m,5H),5.199(s,2H),4.738-4.717(m,1H),3.223(s,2H),1.998(m,2H),1.695-1.623(m,4H);13C-NMR(75MHz,DMSO-d6):δ/ppm=172.21,165.29,159.78,147.93,144.05,142.33,139,79,138.64,136.40,135.30,131.10,130.53,130.53,129.53,128.86,128.86,128.48,128.25,128.25,124.30,124.20,122.73,121.56,120.99,114.98,113.20,66.60,52.49,33.81.
1-对硝基苯基-β-咔啉-3-甲酰-L-脯氨酸苄酯(5q)
产量:78mg(50%)Mp:116-118℃。ESI-MS(m/e):521[M+H]+;(c=0.5,CH3OH);IR(KBr):2953,2880,1742,1605,1520,1456,1410,1344,1171,852,739,696;1H-NMR(300MHz,DMSO-d6):δ/ppm=8.835(s,1H),8.451(dd,J=8.1Hz,J=13.8Hz,3H),8.306(dd,J=8.1Hz,J=22.2Hz,2H),8.156(d,J=8.4Hz,1H),7.683-7.577(m,2H),7.433-7.324(m,5H),7.108-7.038(m,1H),6.903(d,J=6.9Hz,1H),5.199(s,2H),4.148-4.019(m,1H),3.793-3.749(m,2H),1.851-1.799(m,2H),1.211-1.113(m,2H);13C-NMR(75MHz,DMSO-d6):δ/ppm=166.36,165.91,147.80,144.45,144.13,142.95,141.98,137.82,134.15,130.76,130.23,129.54,128.90,128.41,128.26,128.20,128.14,127.83,124.48,124.21,122.67,121.46,120.92,117.18,113.01,66.19,60.64,48.81,25.87,22.10.
1-对硝基苯基-β-咔啉-3-甲酰-L-赖氨酸苄酯(5r)
产量:75mg(45%)。Mp:136-138℃;ESI-MS(m/e):552[M+H]+; IR(KBr):3728,3705,3628,3595,3385,2941,1738,1661,1520,1495,1346.31,1246,1177,1150,1109,853,739,675,656;1H-NMR(300MHz,DMSO-d6):δ/ppm=12.172(d,J=6.3Hz,1H),8.948(s,1H),8.472(m,4H),7.960-7.835(m,4H),7.736-7.589(m,2H),7.435-7.221(m,8H),5.203(s,2H),4.488(s,1H),2.917-2.729(m,1H),2.679-2.659(m,1H),2.341-1.843(m,4H),1.673-1.546(m,2H),1.446-1.423(m,2H);13C-NMR(75MHz,DMSO-d6):δ/ppm=172.28,165.17,147.96,144.01,142.24,139.85,138.60,136.42,135.18,131.10,130.57,129.95,129.62,129.39,128.87,128.49,128.27,127.06,126.87,124.32,124.32,122.73,121.04,114.95,113.18,66.59,63.33,33.81,30.93,25.79,21.52.
实验例1化合物5a-r抑制肿瘤细胞增殖活性评价
本发明的化合物5a-r均用含1%DMSO的PBS配制。共使用了S180(小鼠肉瘤细胞)、HL-60(人早幼粒白血病细胞)、K562(慢性粒细胞白血病细胞)、H22(小鼠肝癌细胞)和SH-SY5Y(人神经瘤母细胞)4株肿瘤细胞。
将生长状态良好、处于对数生长期的SH-SY5Y、HL-60、H22、K562细胞分别按照3×104个/ml、3×104个/ml、3×104个/ml、4×104个/ml的密度接种于96孔板,每孔100μL。在37℃、5%CO2培养箱中培养4小时,按预设的浓度梯度60μM、20μM、8nM和2nM加入经灭菌处理的本发明的化合物,对照组加入等体积溶解样品的溶媒。继续培养48小时后,每孔加25μL浓度为5mg/ml的MTT溶液,置于37℃孵育4小时,小心除去上清液(悬浮细胞经离心后除去上清液)后每孔加入100μL DMSO (二甲基亚砜),振荡约15min溶解沉淀。立即于酶标仪上570nm波长下测定O.D.(吸光度)值。计算抑瘤率及IC50。结果列入表1。结果表明本发明的部分化合物对3株肿瘤细胞增殖都有比较明确的抑制作用。
表1化合物5a-r抑制肿瘤细胞增殖的IC50(μM)a
a)n=9
其余未标注化合物其IC50均大于100μM。
实验例2化合物5a-r在S180小鼠模型上的抗肿瘤活性
测定前将本发明的化合物加吐温80助溶,溶于生理盐水。无菌条件下取接种于ICR小鼠7-10天的S180肉瘤,加入适量生理盐水配制成瘤细胞悬液,细胞数为2×107/ml,接种于健康雄性ICR小鼠前肢腋皮下,每只小鼠注射0.2ml。肿瘤接种24h后,治疗组小鼠每日腹腔注射0.2ml本发明化合物的水溶液,连续给药7天,剂量为8.9μmol/kg。空白组小鼠每日腹腔注射0.2ml生理盐水。以阿霉素(剂量为4μmol/kg)作阳性对照。实验进行至第8天,称小鼠体重,并剖取各组小鼠的肿瘤称重,最后统计各组动物的抑瘤率。实体瘤的疗效以瘤重抑制百分率表示,计算如下:瘤重抑制率%=(1-给药组瘤重/空白组瘤重)×100%。结果列入表2。表2的数据表明在8.9μmol/kg剂量下化合物5e,5f,5h和5q的活性最强。
表2.化合物5a-r的体内抗肿瘤活性a
a)n=12,瘤重用均值±SDmg表示;b)与生理盐水组比p<0.01;c)与生理盐水组比p<0.05。
实验例3化合物5e的剂量依赖实验
按照实验例2的方法,选择活性较强的5e测定8.9μmol/kg、0.89μmol/kg和0.089μmol/kg三种剂量下的活性,结果见表3。表3的数据表明,在8.9μmol/kg和0.89μmol/kg剂量下5e都具有明显的抗肿瘤活性,而在0.089μmol/kg的剂量下5e不再显示抗肿瘤活性。三种剂量下的活性显示明显差异,呈现剂量依赖关系。
表3三种剂量5e的体内抗肿瘤活性a
a)n=12,瘤重用均值±SDmg表示;b)与生理盐水、0.89μmol/kg5e及0.089μmol/kg5e比p<0.01;c)与生理盐水比p<0.01。
Claims (22)
1.一类1-对硝基苯基-β-咔啉-3-甲酰氨基酸苄酯化合物,其结构式为通式I所示:
其中AA选自缬氨酸残基,亮氨酸残基,异亮氨酸残基,苯丙氨酸残基,丝氨酸残基,酪氨酸残基,蛋氨酸残基,苄基保护的谷氨酸残基,苄基保护的天冬氨酸残基,脯氨酸残基,甘氨酸残基或赖氨酸残基。
3.根据权利要求1所述的化合物,所述AA选自L-缬氨酸残基,L-亮氨酸残基,L-异亮氨酸残基,L-苯丙氨酸残基,L-丝氨酸残基,L-酪氨酸残基,L-蛋氨酸残基,苄基保护的L-谷氨酸残基,苄基保护的L-天冬氨酸残基,L-脯氨酸残基,甘氨酸残基,L-赖氨酸残基。
4.根据权利要求2所述的化合物的中间体,所述AA选自L-缬氨酸残基,L-亮氨酸残基,L-异亮氨酸残基,L-苯丙氨酸残基,L-丝氨酸残基,L-酪氨酸残基,L-蛋氨酸残基,苄基保护的L-谷氨酸残基,苄基保护的L-天冬氨酸残基,L-脯氨酸残基,甘氨酸残基,L-赖氨酸残基。
5.一种制备权利要求1所示化合物的方法,包括如下步骤:
1)制备色氨酸甲酯;
2)由色氨酸甲酯与对硝基苯甲醛制备(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯;
3)将(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯皂化,制备得(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸;
4)将(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸与氨基酸苄酯或其衍生物偶联制备得到如权利要求2所示的(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉酰氨基酸苄酯;
5)将(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉酰氨基酸苄酯氧化制备得到平面结构的如权利要求1所示的1-对硝基苯基-β-咔啉-3-甲酰氨基酸苄酯。
6.根据权利要求5所述的制备方法,其中步骤1)中是在甲醇溶液中滴加二氯亚砜,然后加入色氨酸,制备得到色氨酸甲酯。
7.根据权利要求5所述的制备方法,其中步骤2)是在浓盐酸的甲醇溶液中,色氨酸甲酯与对硝基苯甲醛进行Pictet-SpengLer缩合,得到的(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯粗品用柱色谱进行分离,得到(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯纯品。
8.根据权利要求5所述的制备方法,其中步骤3)是在冰盐浴下向(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯四氢呋喃溶液滴加2N氢氧化钠溶液至pH为12,制备得到(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸。
9.根据权利要求5所述的制备方法,其中步骤4)是在二环己基羰二亚胺(DCC),N-羟基苯并三氮唑(HOBt)和N-甲基吗啉(NMM)存在下,将(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸与氨基酸苄酯或其衍生物偶联制备(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉酰氨基酸苄酯;
其中所述氨基酸苄酯或其衍生物选自缬氨酸苄酯,亮氨酸苄酯,异亮氨酸苄酯,苯丙氨酸苄酯,丝氨酸苄酯,酪氨酸苄酯,蛋氨酸苄酯,谷氨酸双苄酯,天冬氨酸双苄酯,甘氨酸苄酯,叔丁氧羰基赖氨酸苄酯。
10.根据权利要求9所述的制备方法,其中氨基酸苄酯或其衍生物中的氨基酸选自L-构型的氨基酸。
11.根据权利要求5所述的制备方法,其中步骤4)中,当偶联脯氨酸苄酯时,先把(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸制备为N-叔丁氧羰基-(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸,再与脯氨酸苄酯偶联,然后在盐酸乙酸乙酯溶液中脱去叔丁氧羰基。
12.根据权利要求11所述的制备方法,其中所述脯氨酸苄酯选自L-构型的脯氨酸苄酯。
13.根据权利要求5所述的制备方法,其中步骤5)是向(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉酰氨基酸苄酯的丙酮溶液中加入高锰酸钾,制备得到1-对硝基苯基-β-咔啉-3-甲酰氨基酸苄酯。
14.一种制备权利要求2所示化合物的方法,包括如下步骤:
1)制备色氨酸甲酯;
2)由色氨酸甲酯与对硝基苯甲醛制备(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯;
3)将(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯皂化,制备得(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸;
4)将(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸与氨基酸苄酯或其衍生物偶联制备得到如权利要求2所示的(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉酰氨基酸苄酯;
15.根据权利要求14所述的制备方法,其中步骤1)中是在甲醇溶液中滴加二氯亚砜,然后加入色氨酸,制备得到色氨酸甲酯。
16.根据权利要求14所述的制备方法,其中步骤2)是在浓盐酸的甲醇溶液中,色氨酸甲酯与对硝基苯甲醛进行Pictet-SpengLer缩合,得到的(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯粗品用柱色谱进行分离,得到(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯纯品。
17.根据权利要求14所述的制备方法,其中步骤3)是在冰盐浴下向(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯四氢呋喃溶液滴加2N氢氧化钠溶液至pH为12,制备得到(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸。
18.根据权利要求14所述的制备方法,其中步骤4)是在二环己基羰二亚胺(DCC),N-羟基苯并三氮唑(HOBt)和N-甲基吗啉(NMM)存在下,将(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸与氨基酸苄酯或其衍生物偶联制备(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉酰氨基酸苄酯;
其中所述氨基酸苄酯或其衍生物选自缬氨酸苄酯,亮氨酸苄酯,异亮氨酸苄酯,苯丙氨酸苄酯,丝氨酸苄酯,酪氨酸苄酯,蛋氨酸苄酯,谷氨酸双苄酯,天冬氨酸双苄酯,甘氨酸苄酯,叔丁氧羰基赖氨酸苄酯。
19.根据权利要求18所述的制备方法,其中氨基酸苄酯或其衍生物中的氨基酸选自L-构型的氨基酸。
20.根据权利要求14所述的制备方法,其中步骤4)中,当偶联脯氨酸苄酯时,先把(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸制备为N-叔丁氧羰基-(1R,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉-3-羧酸,再与脯氨酸苄酯偶联,然后在盐酸乙酸乙酯溶液中脱去叔丁氧羰基。
21.根据权利要求20所述的制备方法,其中所述脯氨酸苄酯选自L-构型的脯氨酸苄酯。
22.权利要求1所述的1-对硝基苯基-β-咔啉-3-甲酰氨基酸苄酯化合物在制备抗肿瘤药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010177112 CN102250202B (zh) | 2010-05-19 | 2010-05-19 | 1-对硝基苯基-β-咔啉-3-甲酰氨基酸苄酯及其合成方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010177112 CN102250202B (zh) | 2010-05-19 | 2010-05-19 | 1-对硝基苯基-β-咔啉-3-甲酰氨基酸苄酯及其合成方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102250202A CN102250202A (zh) | 2011-11-23 |
CN102250202B true CN102250202B (zh) | 2013-08-28 |
Family
ID=44977803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010177112 Expired - Fee Related CN102250202B (zh) | 2010-05-19 | 2010-05-19 | 1-对硝基苯基-β-咔啉-3-甲酰氨基酸苄酯及其合成方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102250202B (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103159827B (zh) * | 2011-12-13 | 2016-03-30 | 首都医科大学 | (1R,3S)-1-对硝基苯基-四氢-β-咔啉酰氨基酸、其合成、抗栓活性和应用 |
CN103374056B (zh) * | 2012-04-20 | 2017-02-08 | 首都医科大学 | 1‑乙酰基‑β‑咔啉‑3‑甲酰氨基酸苄酯、其合成和应用 |
CN103450332B (zh) * | 2012-06-01 | 2016-03-30 | 首都医科大学 | 苯乙烯-β-咔啉修饰的三肽苄酯,其制备,抗肿瘤活性和应用 |
CN103450335B (zh) * | 2012-06-01 | 2015-09-09 | 首都医科大学 | β-咔啉酰色氨酰色氨酰氨基酸苄酯、其合成、抗肿瘤作用及应用 |
CN103509011B (zh) * | 2012-06-18 | 2015-09-09 | 首都医科大学 | 1-(4-羟基-3-甲酰氨基酸基-苯基)-β-咔啉、制备、抗炎和抗肿瘤活性及应用 |
CN104231042A (zh) * | 2013-06-05 | 2014-12-24 | 首都医科大学 | 9-甲氧甲基-β-咔啉-3-甲酰氨基酸苄酯,其合成,抗肿瘤活性与应用 |
CN104211699A (zh) * | 2013-06-05 | 2014-12-17 | 首都医科大学 | β-咔啉衍生物,其制备,纳米结构,抗肿瘤活性和应用 |
CN104211700B (zh) * | 2013-06-05 | 2016-08-10 | 首都医科大学 | 咔啉羧酸类似物,其合成,纳米结构,抗肿瘤活性和应用 |
CN104211768B (zh) * | 2013-06-05 | 2017-10-10 | 首都医科大学 | β‑咔啉‑3‑羧酸与寡肽的缀合物,其制备,纳米结构和作为抗肿瘤剂的应用 |
CN107698658B (zh) * | 2015-06-23 | 2021-02-12 | 首都医科大学 | 双[3-(乙酰-Lys-AA-OBzl)-吲哚-2-基]乙烷,其制备,活性和应用 |
CN106543267A (zh) * | 2015-09-16 | 2017-03-29 | 北京益生康华医药技术有限公司 | β-咔啉-3-甲酰-Trp-Lys-Lys-OBzl,其合成和制备抗肝炎药物的应用 |
CN107501391A (zh) * | 2016-06-14 | 2017-12-22 | 首都医科大学 | 1‑取代‑β‑咔啉‑3‑甲酰‑Trp‑Trp‑AA‑OBzl、其合成、活性及应用 |
CN107501392B (zh) * | 2016-06-14 | 2021-06-08 | 首都医科大学 | 1-取代-β-咔啉-3-甲酰-Trp-Trp-Thr-OBzl、其合成及应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1743330A (zh) * | 2004-09-03 | 2006-03-08 | 首都医科大学 | 烟曲霉震颤素c类似物、其合成方法及其用途 |
CN101597289A (zh) * | 2008-06-02 | 2009-12-09 | 首都医科大学 | 2-色氨酰-β-四氢咔啉-3-甲酰基氨基酸苄酯及其制备方法和应用 |
-
2010
- 2010-05-19 CN CN 201010177112 patent/CN102250202B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1743330A (zh) * | 2004-09-03 | 2006-03-08 | 首都医科大学 | 烟曲霉震颤素c类似物、其合成方法及其用途 |
CN101597289A (zh) * | 2008-06-02 | 2009-12-09 | 首都医科大学 | 2-色氨酰-β-四氢咔啉-3-甲酰基氨基酸苄酯及其制备方法和应用 |
Non-Patent Citations (4)
Title |
---|
1-甲基-β-咔啉-3-甲酰甘氨酸的合成;王炜等;《中国新药杂志》;20051231;第14卷(第2期);第174-176页 * |
王炜等.1-甲基-β-咔啉-3-甲酰甘氨酸的合成.《中国新药杂志》.2005,第14卷(第2期), |
薛宝玉等.3S21 ,2 ,3 ,42四氢2β2咔啉232羧酸的结构修饰和抗血栓活性研究.《首都医科大学学报》.2005,第26卷(第1期), |
薛宝玉等.3S21,2,3,42四氢2β2咔啉232羧酸的结构修饰和抗血栓活性研究.《首都医科大学学报》.2005,第26卷(第1期), * |
Also Published As
Publication number | Publication date |
---|---|
CN102250202A (zh) | 2011-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102250202B (zh) | 1-对硝基苯基-β-咔啉-3-甲酰氨基酸苄酯及其合成方法和应用 | |
CN103570727B (zh) | 一种n-苄基色胺酮衍生物及其制备方法和应用 | |
ES2328156T3 (es) | Amidas de acido isoquinolin-3-carboxilico sustituidas, su preparacion y su uso como medicamentos. | |
CN103694238B (zh) | No供体型苦参碱衍生物、其制备方法及医药用途 | |
CN103450199B (zh) | 茶氨酸修饰的咔啉酰氨基酸苄酯、其制备、抗肿瘤活性和应用 | |
JP6034802B2 (ja) | 大環状ラクタムの調製のための方法および中間体 | |
CN103946231B (zh) | 齐墩果酸酰胺化衍生物、及其制备方法和应用 | |
CN106831725B (zh) | 含二氢吲哚啉及类似结构的喹唑啉类化合物及其应用 | |
ES2930081T3 (es) | Pirazolopirimidinas sustituidas útiles como inhibidores de quinasas | |
CN101812059A (zh) | 一氧化氮供体型法尼基硫代水杨酸衍生物、其制备方法及其医药用途 | |
CN102241674A (zh) | 1,1-二甲基-β-咔啉-3-甲酰基氨基酸苄酯的合成和抗肿瘤活性评价 | |
CN105705493A (zh) | 喹唑啉衍生物、其制备方法、药物组合物和应用 | |
CN115353508B (zh) | 5-吡啶-1h-吲唑类化合物、药物组合物和应用 | |
CN105658670A (zh) | 肽-低聚尿素嵌合化合物及其使用方法 | |
CN106866572A (zh) | 一氧化氮供体型β‑榄香烯衍生物及其制备方法和用途 | |
CN105315332A (zh) | CIPPC-AA-OBzl,其制备,纳米结构,活性和应用 | |
CN104230952A (zh) | 含有嘧啶骨架的化合物及其制备方法和用途 | |
CN103304573B (zh) | 石蒜碱类化合物在制备抗肿瘤药物的应用 | |
CN105237533A (zh) | 四氢吡啶并[4,3-d]嘧啶类Hsp90抑制剂及其医药用途 | |
CN106146584B (zh) | 新型胞苷衍生物二聚体及其应用 | |
CN106905193A (zh) | 芳酰基胍基奥司他韦羧酸衍生物及其制备方法和应用 | |
CN105669532A (zh) | 尼莫地平水溶性衍生物及其制备方法和应用 | |
CN105622704A (zh) | 抗肿瘤药物x-toa的制备方法及其应用 | |
WO2014169697A1 (zh) | 长春碱类衍生物及其制备方法和应用 | |
CN107708719A (zh) | 作为组蛋白脱乙酰酶抑制剂的大环硫代酸酯前体药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130828 Termination date: 20180519 |